脑心通胶囊用于缺血性卒中二级预防:临床与临床前证据的Meta分析
Meta分析显示,联合脑心通可显著降低1年复发风险(RR=0.35,95%CI 0.18-0.68,P=0.002)和2年复发风险(RR=0.62,95%CI 0.50-0.77,P<0.001),且未增加出血或其他严重不良事件风险。临床前证据提示其可能减少主动脉病变面积并增强斑块稳定性。
要点
- 脑心通联合标准抗血小板及血管风险管理可降低缺血性卒中复发风险。
- 联合脑心通未增加出血或其他严重不良事件风险。
- 其获益机制可能涉及抗炎、脂代谢调节和肠道稳态调节。
核心结论
- 脑心通联合标准抗血小板治疗和血管风险管理可降低缺血性卒中复发风险,且不增加出血或其他严重不良事件风险。
- 其有益效应可能归因于抗炎作用、脂代谢调节和肠道稳态调节。
- 当前证据支持脑心通用于缺血性卒中的二级预防。
研究设计与样本
- 检索电子数据库和注册平台,纳入关于脑心通预防缺血性卒中复发的随机对照试验及探讨其改善动脉粥样硬化机制的动物研究。
- 由两名作者独立进行研究选择、数据提取和质量评价,使用Review Manager软件进行Meta分析。
主要发现
- 与安慰剂或无额外治疗相比,脑心通联合标准治疗显著降低1年内复发性缺血性卒中风险(RR=0.35,95%CI 0.18至0.68,P=0.002)。
- 与安慰剂或无额外治疗相比,脑心通联合标准治疗显著降低2年内复发性缺血性卒中风险(RR=0.62,95%CI 0.50至0.77,P<0.001)。
- 未观察到出血或其他严重不良事件风险升高。
- 临床前证据提示脑心通可能减少主动脉病变面积并增强斑块稳定性。
临床怎么用
- 在标准抗血小板治疗和血管风险管理基础上,可考虑联合脑心通胶囊用于缺血性卒中二级预防。
- 使用脑心通时未增加出血风险,但临床仍需结合患者个体情况评估安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Naoxintong, a Chinese patent medicine, may serve as an adjunctive therapy for the secondary prevention of ischemic stroke. AIM OF THE STUDY: To assess the effectiveness and safety of Naoxintong in preventing recurrent ischemic stroke and to review its preclinical evidence. MATERIALS AND METHODS: A search of electronic databases and registries was performed to locate relevant randomized controlled trials (RCTs) on Naoxintong for preventing ischemic stroke recurrence and animal studies exploring its mechanisms in atherosclerosis improvement. Two authors independently conducted study selection, data extraction, and quality assessment for the included studies. We performed meta-analyses using the Review Manager software. RESULTS: Ten RCTs and eight animal studies were included. Naoxintong, when combined with standard treatments, significantly decreased the risk of recurrent ischemic stroke within one year (risk ratio [RR] = 0.35, 95 % confidence interval [CI] 0.18 to 0.68, P = 0.002) and two years (RR = 0.62, 95 % CI 0.50 to 0.77, P < 0.001), compared to placebo or no additional treatment. There was no elevated risk of bleeding or other serious adverse events. Regarding preclinical evidence, Naoxintong may reduce the aortic lesion area and enhance plaque stability. CONCLUSION: Naoxintong, when used alongside standard antiplatelet therapy and vascular risk management, lowers the risk of recurrent ischemic stroke without elevating the risk of bleeding or other serious adverse events. Its beneficial effects may be attributed to anti-inflammatory actions, lipid metabolism regulation, and gut homeostasis modulation. Current evidence endorses its application for the secondary prevention of ischemic stroke.
引用
- Wang L, Chen Y, Chang Z, et al. Naoxintong capsules for secondary prevention of ischemic stroke: Meta-Analyses of clinical and preclinical evidence. J Ethnopharmacol. 2025. PMID: 40912480. doi:10.1016/j.jep.2025.120535
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。